Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors

Journal of Virology

Volumn 70, Issue 6, 1996, Pages 3763-3769

  Doyon, Louise ^a   Croteau, Gilbert ^a   Thibeault, Diane ^a   Poulin, Francis ^a   Pilote, Louise ^a   Lamarre, Daniel ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 BENZYL 3 (2,6 DIMETHYLPHENOXYACETAMIDO) 2 HYDROXYPROPYL] N TERT BUTYL 4 (4 PYRIDINYLTHIO)PIPECOLAMIDE; BILA 1906 BS; PIPECOLIC ACID DERIVATIVE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; DRUG RESISTANCE; GENE LOCUS; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS GENE;

EID: 0029899093     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.6.3763-3769.1996     Document Type: Article

References (38)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Betageri, R., J. L. Hopkins, D. Thibeault, M. J. Emmanuel, G. C. Chow, M. T. Skoog, P. DeDreu, and K. A. Cohen. 1993. Rapid, sensitive and efficient HPLC assays for HIV-1 proteinase. J. Biomed. Biophys. Methods 27:191-197.
3. Candotti, D., C. Chappey, M. Rosenheim, P. M'Pele, J. M. Huraux, and H. Agut. 1994. High variability of the Gag/pol transframe region among HIV-1 isolates. C.R. Acad. Sci. 317:183-189.
4. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, A. Rolh, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. E. Squires, P. J. Deutsch, and E. A. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (London) 374:569-571.
5. Darke, P. L., and J. R. Huff. 1994. HIV protease as an inhibitor target for the treatment of AIDS. Adv. Pharmacol. 25:399-454.
6. Darke, P. L., R. F. Nutt, S. F. Brady, V. M. Garsky, T. M. Ciccarone, C. H. Leu, P. K. Lumma, R. M. Freidinger, D. F. Veber, and I. S. Sigal. 1988. HIV-1 protease specificity of peptide cleavage is sufficient for processing of Gag and pol polyproteins. Biochem. Biophys. Res. Commun. 156:297-303.
7. Devon, L., D. Thibeault, and D. Lamarre. Unpublished data.
8. Graham, F. L., and A. J. van der Eb. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52:456.
9. Higuchi, R., B. Krummel, and R. K. Saiki. 1988. A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. Nucleic Acids Res. 16:7351-7367.
10. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (London) 373:123-126.
11. Ho, D. D., T. Toyoshima, H. Mo, D. J. Kempf, D. Norbeck, C. M. Chen, N. E. Wideburg, S. K. Burt, J. W. Erickson, and M. K. Singh. 1994. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol. 68:2016-2020.
12. Jacks, T., M. D. Power, F. R. Masiarz, P. A. Luciw, P. J. Barr, and H. E. Varmus. 1988. Characterization of ribosomal frameshifting in HIV-1 Gagpol expression. Nature (London) 331:280-283.
13. Kaplan, A. H., J. A. Zack, M. Knigge, D. A. Paul, D. J. Kempf, D. W. Norbeck, and R. Swanstrom. 1993. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J. Virol. 67:4050-4055.
14. Kempf, D. J., K. C. Marsh, J. F. Denissen, E. McDonald, S. Vasavanonda, C. A. Flentge, B. E. Green, L. Fino, C. H. Park, X. P. Kong, N. E. Wideburg, A. Saldivar, L. Ruiz, W. M. Kati, H. L. Sham, T. Robins, K. D. Stewart, A. Hsu, J. J. Plattner, J. M. Leonard, and D. W. Norbeck, 1995. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92:2484-2488.
15. Kohl, N. E., E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. A. F. Dixon, E. M. Scolnick, and I. S. Sigal. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85:4686-4690.
16. Kuroda, M. J., M. El-Farrash, S. Choudhury, and S. Harada. 1995. Impaired infectivity of HIV-1 after a single point mutation in the POL gene to escape the effect of protease inhibitors in vitro. Virology 210:212-216.
17. Lin, Y., X. Lin, L. Hong, S. Foundling, R. L. Heinrikson, S. Thaisrivongs, W. Leelamanit, D. Raterman, M. Shah, B. M. Dunn, and J. Tang. 1995. Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type I protease: relationship to drug resistance. Biochemistry 34:1143-1152.
18. Mellors, J. W., B. A. Larder, and R. F. Schinazi. 1995. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int. Antiviral News 3:8-13.
19. Mervis, R. J., N. Ahmad, E. P. Lillehoj, M. G. Raum, F. H. R. Salazar, H. W. Chan, and S. Venkatesan. 1988. The Gag products of human immunodeficiency virus type 1: alignment within the Gag open reading frame, identification of posttranslational modifications, and evidence for alternative Gag precursors. J. Virol. 62:3993-4002.
20. Moody, M. D., S. C. Pettit, W. Shao, L. Everitt, D. D. Loeb, C. A. Hutchison, and R. Swanstrom. 1995. A side chain at position 48 of the human immunodeficiency virus type-1 flap provides an additional specificity determinant. Virology 207:475-485.
21. Myers, G., B. Korber, J. A. Berzofsky, R. F. Smith, and G. N. Pavlakis. 1994. Human retroviruses and AIDS 1994. Los Alamos National Laboratory, Los Alamos, N.Mex.
22. Pargellis, C. A., M. M. Morelock, E. T. Graham, P. Kinkade, S. Pav, K. Lubbe, D. Lamarre, and P. Anderson. 1994. Determination of kinetic rate constants for the binding of inhibitors to HIV-1 protease and for the association and dissociation of active homodimer. Biochemistry 33:12527-12534.
23. Partaledis, J. A., K. Yamaguchi, M. Tisdale, E. E. Blair, C. Falcione, B. Maschera, R. E. Myers, S. Pazhanisamy, O. Futer, A. B. Cullinan, C. M. Stuver, R. A. Byrn, and D. J. Livingston. 1995. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69:5228-5235.
24. Patick, A. K., R. Rose, J. Greytok, C. M. Bechtold, M. A. Hermsmeier, P. T. Chen, J. C. Barrish, R. Zahler, R. J. Colonno, and P. F. Lin. 1995. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J. Virol. 69:2148-2152.
25. Peng, C., B. K. Ho, T. W. Chang, and N. T. Chang. 1989. Role of human immunodeficiency virus type 1-specific protease in core maturation and viral infectivity. J. Virol. 63:2550-2556.
26. Pettit, S. C., S. F. Michael, and R. Swanstrom. 1993. The specificity of the HIV-1 protease. Persp. Drug Discov. Design 1:69-83.
27. Pettit, S. C., J. Simsic, D. D. Loeb, L. Everitt, C. A. Hutchison III, and R. Swanstrom. 1991. Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the p1 amino acid. J. Biol. Chem. 266:14539-14547.
28. Popovic, M., E. Read-Connole, and R. C. Gallo. 1984. T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III. Lancet ii:1472-1473.
29. Popovic, M., M. G. Sarngadharan, E. Read, and R. C. Gallo. 1984. Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224:497-500.
30. Preston, B. D., B. J. Poiesz, and L. A. Loeb. 1988. Fidelity of HIV-1 reverse transcriptase. Science 242:1168-1171.
31. Ratner, L., W. Haseltine, R. Patarca, K. J. Livak, B. Starcich, S. F. Josephs, E. R. Doran, J. A. Rafalski, E. A. Whitehorn, E. Baumeister, L. Ivanoff, S. R. Petteway, Jr., M. L. Pearson, J. A. Lautenberger, T. S. Papas, J. Ghrayab, N. T. Chang, R. C. Gallo, and F. Wong-Staal. 1985. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature (London) 313:277-283.
32. Sardana, V. V., A. J. Schlabach, P. Graham, B. L. Bush, J. H. Condra, J. C. Culberson, L. Gotlib, D. J. Graham, N. E. Kohl, R. L. LaFemina, C. L. Schneider, B. S. Wolanski, J. A. Wolfgang, and E. A. Emini. 1994. Human immunodeficiency virus type I protease inhibitors: evaluation of resistance engendered by amino acid substitutions in the enzyme's substrate binding site. Biochemistry 33:2004-2010.
33. Tong, L., S. Pav, S. Mui, D. Lamarre, C. Yoakim, P. Beaulieu, and P. C. Anderson. 1995. Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptidyl isostere. Structure 3:33-40.
34. Tozser, J., I. Blahah, T. D. Copeland, E. M. Wondrak, and S. Oroszlan. 1991. Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-pol polyproteins. FEBS Lett. 281:77-80.
35. Veronese, F. D. M., R. Rahman, T. D. Copeland, S. Oroszlan, R. C. Gallo, and M. G. Sarngadharan. 1987. Immunological and chemical analysis of p6, the carboxyl-terminal fragment of HIV p15. AIDS Res. Hum. Retroviruses 3:253-254,
36. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature (London) 373:117-122.
37. West, M. L., and D. P. Fairlie. 1995. Targeting HIV-1 protease: a test of drug-design methodologies. Trends Pharm. Sci. 16:67-75.
38. Wondrak, E. M., J. M. Louis, H. de Rocquigny, J. C. Chermann, and B. P. Roques. 1993. The Gag precursor contains a specific HIV-1 protease cleavage site between the NC (p7) and p1 proteins. FEBS Lett. 333:21-24.